Cryo-Cell International, Inc. Annual report pursuant to Section 13 and 15(d)

Intangible Assets (Tables)

12 Months Ended

Nov. 30, 2020

Intangible assets were as follows as of November 30, 2020 and 2019:

	Useful lives	November 30, 2020			November 30, 2019
Patents	10-20 years	$	234,570		$	234,570
Less: Accumulated amortization			(47,150	)		(35,526	)
License agreement	10 years		470,000			470,000
Less: Intangible asset impairment			(185,000	)		(185,000	)
Less: Accumulated amortization			(178,443	)		(155,194	)
Customer relationships – PrepaCyte®CB	15 years		41,000			41,000
Less: Intangible asset impairment			(26,267	)		(26,267	)
Less: Accumulated amortization			(7,122	)		(6,329	)
Brand	1 year		31,000			31,000
Less: Accumulated amortization			(31,000	)		(31,000	)
Customer relationships – Cord:Use	30 years		960,000			960,000
Less: Accumulated amortization			(80,000	)		(48,000	)
Net Intangible Assets		$	1,181,588		$	1,249,254

Expected amortization related to these intangible assets for each of the next five fiscal years and for periods thereafter is as follows:

Fiscal years ending November 30:
2021	$	67,667
2022	$	67,667
2023	$	67,667
2024	$	67,667
2025	$	57,980
Thereafter	$	852,940
Total	$	1,181,588